Table 1.
Patients’characteristics – patients with no prior treatment (n = 32)
| Characteristic | n (%) |
|---|---|
| Tumor stage | |
| cT1c | 6 (18.8) |
| cT2a | 1 (3.1) |
| cT2b | 3 (9.4) |
| cT2c | 4 (12.5) |
| cT3a | 5 (15.6) |
| cT3b | 3 (9.4) |
| Tx | 6 (18.8) |
| cN1 | 32 (100) |
| cM0 | 30 (93.75) |
| cM1a | 1 (3.1) |
| cM1b | 0 |
| D’Amico risk group | |
| Low | 2 (6.3) |
| Intermediate | 4 (12.5) |
| High | 26 (81.25) |
| Initial PSA level (ng/ml) | |
| Mean | 32.78 |
| Median | 21.71 |
| Range | 5.1–198.0 |
| PSA at the time of PET/CT (ng/ml) | |
| Mean | 22.7 |
| Median | 12.5 |
| Range | 0.03–99.0 |
| Gleason score | |
| ≤6 | 7 (21.88) |
| 7 (3 + 4) | 3 (9.4) |
| 7 (4 + 3) | 4 (12.5) |
| 8 | 1 (3.1) |
| 9 | 8 (25.0) |
| missing | 9 (28.1) |
| Age (years) | |
| Mean | 69.2 |
| Median | 71 |
| Range | 51–80 |
| Time from initial diagnosis until PET/CT (months) | |
| Mean | 10.8 |
| Median | 1 |
| Range | 0–83 |